GLP-1 vs Qsymia: Weight Loss Medication Head-to-Head

Introduction

Qsymia was approved in 2012 as the first new prescription weight loss combination drug in years. It pairs phentermine (an appetite suppressant) with topiramate (an antiepileptic that also reduces appetite and food reward). For nearly a decade it was the most effective oral weight loss prescription available, posting around 10% mean weight loss in its key trials.

Then semaglutide and tirzepatide changed the field. GLP-1 receptor agonists routinely produce 15% to 21% weight loss, beating Qsymia’s numbers by a meaningful margin. They’ve reset what “best in class” means for obesity pharmacotherapy.

Qsymia isn’t obsolete. It’s oral, it’s been on the market for over a decade, and for the right patient it produces real results at a different price point. But comparing it head-to-head with modern GLP-1s requires being honest about the data.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Does Qsymia Work?

Qsymia combines two FDA-approved drugs into one extended-release capsule. Phentermine is a sympathomimetic appetite suppressant that triggers norepinephrine release in the central nervous system. Topiramate is an antiepileptic with multiple proposed mechanisms (GABA modulation, glutamate antagonism, carbonic anhydrase inhibition) that produces appetite suppression and reduces food cravings.

Quick Answer: Qsymia produces 10% to 11% mean weight loss at full dose over 56 weeks (CONQUER trial, Gadde et al. 2011 Lancet)

The combination is more effective than either drug alone at lower doses, and the lower doses reduce side effects of both components. Qsymia comes in four strengths: 3.75/23 mg (starter), 7.5/46 mg (recommended), 11.25/69 mg (titration), and 15/92 mg (top dose).

GLP-1 receptor agonists mimic an endogenous gut hormone, slow gastric emptying, increase satiety, and reduce food reward signaling. The mechanism is entirely different from Qsymia’s.

Which Produces More Weight Loss?

GLP-1s win on average, but Qsymia is the strongest oral option. The CONQUER trial (Gadde et al. 2011 Lancet) tested Qsymia in 2,487 adults with overweight or obesity plus comorbidities. At 56 weeks, mean weight loss was 9.8% at the recommended dose and 10.9% at the top dose, versus 1.4% on placebo. The EQUIP trial (Allison et al. 2012 Obesity) in patients with class II to III obesity showed similar results.

Semaglutide 2.4 mg produced 14.9% at 68 weeks in STEP 1. Tirzepatide 15 mg produced 20.9% at 72 weeks in SURMOUNT-1. Even semaglutide’s lower diabetes dose of 1 mg often matches Qsymia’s full-dose performance.

So Qsymia is closer to GLP-1s than older drugs like phentermine alone or orlistat, but it still underperforms semaglutide by 4 to 5 percentage points and tirzepatide by 9 to 10 points.

What’s the Side Effect Profile?

Qsymia’s side effects come from both components. Phentermine contributes increased heart rate, insomnia, dry mouth, and constipation. Topiramate contributes paresthesia (tingling in hands and feet), taste changes (especially carbonated beverages tasting “flat” or metallic), cognitive slowing, word-finding difficulty, and kidney stone risk.

The “soda tastes weird” effect is so characteristic of topiramate that many patients recognize it immediately. Cognitive side effects (“topa-dopa”) can be significant at higher doses and limit some patients’ tolerance.

Qsymia is teratogenic. Topiramate is associated with cleft lip and cleft palate in babies born to women who took it during pregnancy. The drug has a REMS program requiring monthly pregnancy testing in women of reproductive potential.

GLP-1 side effects are primarily gastrointestinal: nausea, vomiting, diarrhea, constipation during dose escalation. GLP-1s are also pregnancy-contraindicated but lack topiramate’s specific teratogenic profile.

How Is Qsymia Dosed?

Qsymia is a once-daily oral capsule taken in the morning. Patients start at 3.75/23 mg for 14 days, step up to 7.5/46 mg (the recommended maintenance dose), and titrate higher to 11.25/69 mg or 15/92 mg if needed for additional weight loss. The slow titration helps minimize side effects, especially the paresthesia and cognitive effects.

GLP-1s are weekly subcutaneous injections. Semaglutide starts at 0.25 mg/week and titrates over 16 weeks to 2.4 mg. Tirzepatide starts at 2.5 mg/week and titrates over 20 weeks to 15 mg. Both require dose escalation to manage GI side effects.

Patients who prefer pills over injections often pick Qsymia. Patients who prefer weekly dosing over daily often pick GLP-1s.

What Does Each Cost?

Qsymia’s manufacturer offers cash pricing through a direct program. The most common pricing tier runs around $98 to $200/month depending on dose and program participation. Without the program, retail can be $200 to $300+/month. Insurance coverage varies.

GLP-1 brand prices are higher. Brand Wegovy® is around $1,349/month, Zepbound® around $1,086/month. Compounded semaglutide and tirzepatide through telehealth platforms like TrimRx typically run $200 to $500/month, which is in the same range as Qsymia direct pricing.

At brand list, Qsymia is dramatically cheaper. At compounded GLP-1 pricing, the cost gap narrows considerably, and the weight loss difference may justify the higher cost for many patients.

Key Takeaway: Tirzepatide reaches 20.9% at 72 weeks (SURMOUNT-1, Jastreboff et al. 2022 NEJM)

Cardiovascular and Metabolic Effects

Qsymia produces modest improvements in blood pressure, lipids, and glycemic measures, mostly driven by the weight loss itself. Long-term cardiovascular outcome data is limited. The phentermine component slightly raises heart rate; the topiramate component is neutral or slightly favorable for blood pressure.

GLP-1s have transformed cardiovascular outcome data. The SELECT trial (Lincoff et al. 2023 NEJM) tested semaglutide 2.4 mg in 17,604 adults with overweight or obesity plus cardiovascular disease and showed a 20% reduction in major adverse cardiovascular events. The FLOW trial (Perkovic et al. 2024 NEJM) showed semaglutide reduced kidney disease progression and cardiovascular death by 24% in diabetic kidney disease.

For patients with established cardiovascular disease, the evidence increasingly favors GLP-1s over Qsymia.

Who’s a Good Candidate for Qsymia?

Qsymia fits patients who prefer oral dosing, have moderate weight to lose (20 to 40 pounds), can tolerate the topiramate side effect profile, and have a budget constraint or insurance that doesn’t cover GLP-1s for obesity. It also fits patients with migraine (topiramate is approved for migraine prevention) who could get dual benefit.

It doesn’t fit patients with cardiovascular disease (phentermine concern), kidney stone history, glaucoma, hyperthyroidism, women planning pregnancy, or patients with cognitive concerns.

Who’s a Good Candidate for GLP-1?

GLP-1s fit patients with substantial obesity needing 15%+ weight loss, those with type 2 diabetes, cardiovascular disease, sleep apnea, or chronic kidney disease, patients comfortable with weekly injection, and those committed to long-term therapy. TrimRx’s free assessment quiz screens eligibility for compounded semaglutide and tirzepatide.

Can Qsymia and GLP-1s Be Combined?

Yes, off-label, in obesity medicine practice. The mechanisms are complementary. The combination has to be screened for phentermine’s cardiovascular contraindications and topiramate’s renal and cognitive effects, plus the additive nausea risk of GLP-1 plus topiramate. Most patients won’t need both. For plateau cases, it’s a recognized strategy.

FAQ

Is Qsymia a Controlled Substance?

Yes, Qsymia is Schedule IV because of the phentermine component. This affects how it can be prescribed and refilled, with limits on remote prescribing in some states.

Why Does Qsymia Make Soda Taste Weird?

Topiramate inhibits carbonic anhydrase, which is involved in carbonated beverage taste perception. Many patients on topiramate report that soda tastes flat or metallic. The effect typically appears within the first weeks and can persist for the duration of treatment.

Can Qsymia Cause Kidney Stones?

Yes, topiramate increases the risk of kidney stones, particularly calcium phosphate stones, by inhibiting carbonic anhydrase in the kidney. Staying well-hydrated reduces but doesn’t eliminate this risk. Patients with a personal or strong family history of kidney stones may not be good candidates.

Will Qsymia Affect My Mood?

Topiramate can cause cognitive slowing, word-finding difficulty, and in some patients mood changes including depression. Bupropion has a separate boxed warning for suicidal thoughts in young adults. Patients with a history of depression should discuss this with their prescriber.

Can I Take Qsymia Long-term?

Qsymia is approved for chronic weight management, unlike phentermine monotherapy which has only short-term approval. Long-term trials extended out to 108 weeks (SEQUEL) showed sustained weight loss with continued use.

How Long Does Qsymia Take to Work?

Most patients see appetite reduction within the first weeks and meaningful weight loss by month 3. Peak weight loss is typically reached between months 6 and 12 at the maintenance or higher doses.

Does Qsymia Help with Binge Eating?

The topiramate component has shown benefit for binge eating disorder in some trials, though it isn’t FDA-approved for that indication. Patients with binge eating patterns sometimes notice improved control on Qsymia.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.